Table 2.
Difference in 12 month BP among patients with hypertension started on a new oral diabetic medication
| Systolic BP at 12 months among cohort | Model 1 Unadjusted |
Model 2 Association of OAD on 12 month BP adjusted for covariates † |
Model 3 Association of BMI change on 12 month BP adjusted for covariates ‡ |
Model 4 Association of OAD and BMI change on 12 month BP adjusted for covariates § |
|---|---|---|---|---|
| Total patients (N=3770) | ||||
| Intercept* | 133.40 | 135.24 | 136.40 | 136.14 |
| Sulfonylurea | 2.94 (1.74, 4.14) | 1.40 (0.23, 2.57) | -- | 0.31 (−0.92, 1.53) |
| BMI change | -- | -- | 1.09 (0.77, 1.40) | 1.05 (0.73, 1.38) |
| Sensitivity Analysis, multiple imputation cohort (N=5201) | ||||
| Intercept* | 134.00 | 136.93 | 137.85 | 137.87 |
| Sulfonylurea | 2.34 (1.31, 3.38) | 1.02 (0.01, 2.02) | -- | −0.09 (−1.13, 0.96) |
| BMI change | -- | -- | 1.16 (0.88, 1.44) | 1.16 (0.86, 1.45) |
| Systolic BP at 12 months among subgroups eGFR >60ml/min/1.73m2 (N=3006) | ||||
| Intercept * | 133.55 | 135.12 | 136.15 | 136.02 |
| Sulfonylurea | 3.01 (1.62, 4.39) | 1.38 (0.09, 2.68) | -- | 0.27 (−1.09, 1.62) |
| BMI change | -- | -- | 1.06 (0.71, 1.40) | 1.04 (0.68, 1.40) |
| No Congestive Heart Failure (N=3564) | ||||
| Intercept * | 133.59 | 135.73 | 136.86 | 136.61 |
| Sulfonylurea | 3.08 (1.85, 4.31) | 1.43 (0.24, 2.63) | -- | 0.25 (−1.00, 1.50) |
| BMI change | -- | -- | 1.17 (0.85, 1.49) | 1.14 (0.81, 1.48) |
| No hospitalization (N=3392) | ||||
| Intercept * | 133.47 | 135.68 | 136.70 | 136.49 |
| Sulfonylurea | 3.22 (1.95, 4.49) | 1.43 (0.20, 2.67) | -- | 0.26 (−1.04, 1.56) |
| BMI change | -- | -- | 1.19 (0.84, 1.53) | 1.16 (0.80, 1.52) |
| White (N=3084) | ||||
| Intercept * | 133.05 | 135.91 | 137.04 | 136.55 |
| Sulfonylurea | 2.87 (1.56, 4.17) | 1.36 (0.09, 2.63) | -- | 0.18 (−1.13, 1.50) |
| BMI change | -- | -- | 1.15 (0.82, 1.49) | 1.13 (0.78, 1.48) |
| Black (N=385) | ||||
| Intercept * | 135.91 | 130.24 | 131.3 | 130.74 |
| Sulfonylurea | 2.19 (−1.94, 6.33) | 1.54 (−2.76, 5.84) | -- | 1.02 (−3.41, 5.44) |
| BMI change | -- | -- | 0.68 (−0.73, 2.10) | 0.58 (−0.87, 2.04) |
Intercept represents 12 month systolic BP among those who are metformin users.
Model 2-Considers patient persistent on incident regimen until they do not have OAD medications for 90 days. Adjusted for age, sex, race, year of index prescription, baseline HbA1c, BMI, Systolic BP (third degree polynomial), serum creatinine, history of cardiovascular disease, marital status, baseline number of medications, number of outpatient visits, history of hospitalization; Model for entire cohort and sensitivity analysis also adjust for antipsychotic medications, corticosteroid use, thiazide diuretics, angiotensin receptor blockers (ARB), angiotensin converting enzyme inhibitors (ACE), and other diuretics.
Model 3-No OAD in model. Adjusted for age, sex, race, year of index prescription, baseline HbA1c, BMI, Systolic BP (third degree polynomial), serum creatinine, history of cardiovascular disease, marital status, baseline number of medications, number of outpatient visits, history of hospitalization and change in BMI between cohort entry and 12 month systolic BP. Model for entire cohort and sensitivity analysis also adjust for antipsychotic medications, corticosteroid use, thiazide diuretics, angiotensin receptor blockers (ARB), angiotensin converting enzyme inhibitors (ACE), and other diuretics.
Model 4 Considers patients persistent on incident regimen until they do not have OAD medications for 90 days. Adjusted for age, sex, race, year of index prescription, baseline HbA1c, BMI, Systolic BP (third degree polynomial), serum creatinine, history of cardiovascular disease, marital status, baseline number of medications, number of outpatient visits, history of hospitalization and change in BMI between cohort entry and 12-month systolic BP. Model for entire cohort and sensitivity analysis also adjust for antipsychotic medications, corticosteroid use, thiazide diuretics, angiotensin receptor blockers (ARB), angiotensin converting enzyme inhibitors (ACE), and other diuretics.